Drug intelligence / Profile preview

AMLOTUS-L + AMLOTUS-LH

Development stage
Unknown
Lead developer
Arrotex
Modality
Small Molecules
Administration
Oral
01

Overview

AMLOTUS-L and AMLOTUS-LH are fixed-dose combination antihypertensive medications developed and manufactured by Arrow Pharmaceuticals, a generic pharmaceutical manufacturer based in Nepal. These products contain two active ingredients: losartan potassium, an angiotensin II type 1 (AT1) receptor antagonist, and amlodipine besylate, a dihydropyridine L-type calcium channel blocker. Losartan works by selectively blocking the binding of angiotensin II to the AT1 receptor in many tissues, such as vascular smooth muscle and the adrenal gland, thereby blocking the vasoconstrictor and aldosterone-secreting effects of angiotensin II. Amlodipine inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle, leading to peripheral vasodilation and a reduction in blood pressure. AMLOTUS-L contains 50 mg of losartan potassium and 5 mg of amlodipine, while AMLOTUS-LH contains 25 mg of losartan potassium and 5 mg of amlodipine. These oral film-coated tablets are used for the management of hypertension, particularly in patients who require dual therapy for adequate blood pressure control.

Other names
Losartan Potassium & AmlodipineLosartan Potassium + Amlodipine Besylate
02

Targets

AGTR1 (Angiotensin II Type-1 receptor)LTCC (Voltage-gated calcium channel (L-type))

Beyond the preview

Go deeper on AMLOTUS-L + AMLOTUS-LH.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on AMLOTUS-L + AMLOTUS-LH.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call